Araújo Lorena Ulhôa, Albuquerque Kemile Toledo de, Kato Kelly Cristina, Silveira Gleiciely Santos, Maciel Náira Rezende, Spósito Pollyanna Álvaro, Barcellos Neila Márcia Silva, Souza Jacqueline de, Bueno Márcia, Storpirtis Sílvia
Departamento de Farmácia, Escola de Farmácia, Universidade Federal de Ouro Preto, Ouro Preto, MG, Brasil.
Rev Panam Salud Publica. 2010 Dec;28(6):480-92. doi: 10.1590/s1020-49892010001200010.
The Brazilian generic drugs policy was implemented in 1999 with the aim of stimulating competition in the market, improve the quality of drugs and improve the access of the population to drug treatment. The process of implementing this policy allowed the introduction and discussion of concepts that had never before been used in the context of drug registration in Brazil: bioavailability, bioequivalence, pharmaceutical equivalence, generic drugs, biopharmaceutical classification system, biowaiver. The present article provides definitions for these concepts in the context of Brazilian legislation as well as a historical and chronological description of the implementation of the generic drugs policy in Brazil, including a list of current generic drug legislation. This article contributes to the understanding of the Brazilian generic drugs policy and facilitates the search for information concerning the legal requirements for registration of drugs in Brazil.
巴西的仿制药政策于1999年实施,旨在刺激市场竞争、提高药品质量并改善民众获得药物治疗的机会。该政策的实施过程引入并讨论了一些此前在巴西药品注册背景下从未使用过的概念:生物利用度、生物等效性、药学等效性、仿制药、生物药剂学分类系统、生物豁免。本文在巴西立法背景下对这些概念进行了定义,并按时间顺序对巴西仿制药政策的实施进行了历史性描述,包括现行仿制药立法清单。本文有助于理解巴西的仿制药政策,并便于查找有关巴西药品注册法律要求的信息。